News
Albuminuria reduction fuels finerenone’s kidney benefits
Mediation analyses of finerenone trial data show most of the drug’s kidney benefit and a third of its CVD benefit comes from cutting albuminuria...
News
CKD-EPI eGFR formula surpasses alternatives in young adults
The 2021 race-free CKD-EPI equation for estimating glomerular filtration rate outperformed two alternative formulas in adults aged 18-40 years.
News
Risk calculator for early-stage CKD may soon enter U.S. market
Klinrisk, which estimates an adult’s risk for CKD progression from 20 lab values, may spur more targeted, intensified treatment.
News
Aprocitentan reduces resistant hypertension in CKD
Aprocitentan, a novel dual endothelin antagonist, showed antihypertensive efficacy and manageable safety in people with chronic kidney disease.
News
EMR prompt boosts albuminuria measurement in T2D
An EMR prompt in primary care to measure albuminuria and eGFR in adults with type 2 diabetes boosted screening by about 50%.
News
Higher weight loss on tirzepatide links to seven factors
“These findings may provide valuable information to clinicians and people with type 2 diabetes regarding the likelihood of achieving substantial...
News
FDA gives semaglutide two drug safety–related label changes
The second addition concerns a new adverse reaction that was identified during the postmarketing experience: gastrointestinal ileus, an intestinal...
News
Echocardiography boosts prognostic power in T1D
“MPI has been around for many years, but our technique is rather novel” and has high intra- and inter-observer reproducibility. “It’s highly...
News
FDA panel rejects implanted GLP1-RA dosing device for T2D
“The data show concerning safety signals that need further investigation.”
News
SGLT2i safety in acute heart failure confirmed by new data
Dapagliflozin appeared to improve diuresis and natriuresis while reducing the administered diuretic dose.
News
Screening finds high rates of CVD in diabetes, COPD patients
The study tested a “very simple” symptom questionnaire as the initial screening phase, yet resulted in a CVD diagnostic rate that was two- to...
News
More weight loss linked with more benefit in STEP-HFpEF
“The outcomes we’ve already seen in STEP-HFpEF were largely symptomatic, which are extraordinarily important, but there may be a completely...
News
ESC backs SGLT2 inhibitor plus GLP-1 in diabetes with high CVD risk
Another major change in the new ESC guideline revision is introduction of a CVD risk calculator intended to estimate the risk among people with...
News
Liraglutide fixes learning limit tied to insulin resistance
The normalization in associative learning that one dose of liraglutide produced in people with obesity “fits with studies showing that these drugs...
News
Wegovy scores HFpEF benefits in people with obesity
The results “indicate that treatment with semaglutide is a valuable therapeutic approach in the management of patients with HFpEF and obesity.”